Virulence of Streptococcus mutans: revertants of mutant C4. 1980

T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota

Mutant C4, a poor plaque-forming mutant of Streptococcus mutans 6715-HSR, was employed to obtain isolates resembling the parent strain (a plaque former). Seventeen presumptive revertants, as identified by colonial morphology, were isolated from mutant C4 after enrichment cycles in a sucrose-glass beads medium. These isolates displayed properties which resembled the parent in ability to produce plaque, patterns of fermentation, and resistance to streptomycin. In a detailed study, five selected isolates were found to be similar to the parent type 6715-HSR with respect to content of the serotype antigen, sucrose- or dextran-induced cell aggregation, glucosyltransferase and adherence activities, and cariogenicity. Thus, in selection for revertants to parental colonial morphology, the pleiotropic changes in plaque formation, adherence, glycosyltransferase activity, and virulence demonstrated by C4 all concomitantly reverted to their parental phenotypes.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002449 Cell Aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type. Aggregation, Cell,Aggregations, Cell,Cell Aggregations
D005285 Fermentation Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID. Fermentations
D005779 Immunodiffusion Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction. Gel Diffusion Tests,Diffusion Test, Gel,Diffusion Tests, Gel,Gel Diffusion Test,Immunodiffusions,Test, Gel Diffusion,Tests, Gel Diffusion
D005856 Germ-Free Life Animals not contaminated by or associated with any foreign organisms. Axenic Animals,Gnotobiotics,Germfree Life,Animal, Axenic,Animals, Axenic,Axenic Animal,Germ Free Life,Gnotobiotic,Life, Germ-Free,Life, Germfree
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013295 Streptococcus mutans A polysaccharide-producing species of STREPTOCOCCUS isolated from human dental plaque.
D013307 Streptomycin An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis. Estreptomicina CEPA,Estreptomicina Clariana,Estreptomicina Normon,Strepto-Fatol,Strepto-Hefa,Streptomycin GrĂ¼nenthal,Streptomycin Sulfate,Streptomycin Sulfate (2:3) Salt,Streptomycin Sulphate,Streptomycine Panpharma,Strepto Fatol,Strepto Hefa

Related Publications

T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
March 1980, Infection and immunity,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
January 1981, Infection and immunity,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
November 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
May 2004, Frontiers in bioscience : a journal and virtual library,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
January 1985, Progress in clinical and biological research,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
March 1999, Infection and immunity,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
February 1980, Infection and immunity,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
January 1978, Advances in experimental medicine and biology,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
January 1985, Current topics in microbiology and immunology,
T Ikeda, and S Otake, and M Hirasawa, and K Williams, and H Kiyoyono, and J R McGhee, and T Shiota
March 1980, Infection and immunity,
Copied contents to your clipboard!